/ ABSTACT The UAB CCC is the only NCI designated comprehensive cancer center in the states of Alabama, Mississippi, Louisiana and Arkansas, states with higher cancer mortality and significant minority, mostly African American populations. The Cancer Center is in its 44th year of NCI funding and continues its major contributions to translational therapeutics and cancer disparity research with a focus on training minority investigators. The UAB CCC has 242 members who come from 30 departments in 9 UAB schools, Southern Research, and HudsonAlpha Institute for Biotechnology. The members are supported by $92,055,777 in annual direct extramural funding. The UAB CCC is organized into six research programs, two each in basic, translational, and prevention and control ? Inflammation, Immunology & Immunotherapeutics; Cancer Cell Biology; Experimental Therapeutics; Neuro-Oncology; Cancer Chemoprevention; and Cancer Control & Population Sciences. Members published 1,684 cancer focused, peer reviewed publications between 2011 and 2015 of which 24% were intra-programmatic, 16% inter-programmatic, and 53% inter-institutional. These members are supported by eleven shared facilities ? Biostatistics & Bioinformatics, Comprehensive Genomics, High Resolution Imaging, Human Imaging, Mass Spectrometry/2D Proteomics, Microbiome/Gnotobiotic, Preclinical Imaging, Recruitment & Retention, Structural Biology, Tissue Procurement, and Transgenic Animals as well as the developing Pharmacometrics Shared Facility. We have established a Phase I Clinical Trials Program, opened an Advanced Imaging Facility, advanced targets through the Alabama Drug Discovery Alliance, created the UAB Health System Cancer Community Network, and are now a consortium with HudsonAlpha Institute for Biotechnology. In addition to these achievements, we have created an Institute for Cancer Outcomes and Survivorship, and established a critical mass of investigators in energy balance and cancer. We have also expanded our minority training programs that since 2005 have trained 59 scholars resulting in 306 publications, 67 grant submissions with 30 funded, and have had a major impact at Morehouse School of Medicine and Tuskegee University. We have recruited 47 investigators to multiple programs in the Cancer Center since 2010. Strategic plans developed in 2011 with crosscutting themes of Translational Therapeutics, Systems Biomedicine, and Energetics and Cancer continue to be highly relevant today. For the future, we will continue to emphasize translational and cancer disparity research with an emphasis on personalized/genomic medicine, energy balance and cancer, outcomes and survivorship, and early phase clinical trials.

Public Health Relevance

OVERALL COMPONENT PROJECT NARRATIVE The UAB CCC has made a significant contribution to public health that is particularly relevant to the populations served by this Cancer Center who are located in the heart of the Deep South. Our research programs, in addition to their important contributions to translational science, have focused on the unique problems seen in African American populations that include higher incidences and mortality rates from certain cancers, lower age appropriate screening rates, greater obesity from poor diets and less physical activity, greater tobacco use, and lack of access to care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013148-47S5
Application #
9997142
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
1997-03-28
Project End
2021-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
47
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Jimenez, Rachel V; Wright, Tyler T; Jones, Nicholas R et al. (2018) C-Reactive Protein Impairs Dendritic Cell Development, Maturation, and Function: Implications for Peripheral Tolerance. Front Immunol 9:372
Engle, Staci E; Antonellis, Patrick J; Whitehouse, Logan S et al. (2018) A CreER mouse to study melanin concentrating hormone signaling in the developing brain. Genesis 56:e23217
Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625
Kim, Harrison (2018) Modification of population based arterial input function to incorporate individual variation. Magn Reson Imaging 45:66-71
Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397
Park, Misun; Yoon, Young Sup (2018) Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. Korean Circ J 48:974-988
Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431
Dionne-Odom, J Nicholas; Applebaum, Allison J; Ornstein, Katherine A et al. (2018) Participation and interest in support services among family caregivers of older adults with cancer. Psychooncology 27:969-976
Demark-Wahnefried, Wendy; Schmitz, Kathryn H; Alfano, Catherine M et al. (2018) Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89
Bandari, Shyam K; Purushothaman, Anurag; Ramani, Vishnu C et al. (2018) Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 65:104-118

Showing the most recent 10 out of 747 publications